A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma

NCT05765812 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

116

Enrollment

INDUSTRY

Sponsor class

Conditions

Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
Astrocytoma, Grade III

Interventions

DRUG: Debio 0123
DRUG: Temozolomide
RADIATION: Radiotherapy

Sponsor

Debiopharm International SA